Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Directed Clonal Evolution of Drug Resistant BRAF Mutant Melanoma for Cross-Sensitization to MAPK Hyperactivation

Award Number: F32CA271719
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 03/01/2024
PERIOD OF PERFORMANCE END DATE: 02/28/2027

Group Awards By:

View Award Description

Directed Clonal Evolution of Drug Resistant BRAF Mutant Melanoma for Cross-Sensitization to MAPK Hyperactivation - PROJECT SUMMARY/ABSTRACT Targeted cancer therapeutics have traditionally focused on inhibiting activated oncogenic signaling pathways. While such pathway inhibitors have resulted in clinical successes with improved patient response rates and progression free survival, in most cases, they have yet to yield curative responses due to eventual drug resistance. Emerging evidence suggests that context-dependent lethality induced by pathway activation represents a promising unexplored approach for cancer therapeutics with the potential to overcome resistance. The main goal of this project is to demonstrate cancers developing resistance to targeted therapy will gain increased sensitivity to non-cross-resistant, pathway-hyperactivation. Specifically, this project will focus on melanoma, where oncogenic ERK MAPK pathway activation motivated the development of MAPK pathway inhibitors. BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) are used in combination as the standard of care for targeted therapy in BRAFV600E melanoma patients. However, current treatment options, including these targeted therapies and immunotherapies, rarely achieve complete responses due to intrinsic and acquired resistance. Although resistance to MAPK pathway inhibition is predominantly mediated by MAPK reactivation, the intratumoral heterogeneity of resistance mechanisms complicate and curtail efforts to combat resistance. Increased susceptibility to MAPK hyperactivation occurs through the same mechanisms that make cells resistant to BRAFi/MEKi, suggesting cycling treatment for MAPK inhibition followed by MAPK activation would induce collateral sensitivity and avoid resistance development. This proposal will employ high complexity cellular barcode tracing as well as BRAFi/MEKi resistant xenograft models to investigate the efficacy of driving tumor clonal evolution toward BRAFi/MEKi resistance for maximal sensitivity to lethal MAPK hyperactivation resulting in tumor eradication. Furthermore, dual-knockout CRISPR screening strategies will be employed to identify the molecular mechanisms mediating MAPK hyperactivation lethality. The proposed therapeutic approach is based on 1) preliminary work observing selective sensitivity of MAPKi resistant melanoma to lethal MAPK hyperactivation and 2) non-cross resistance mechanisms for MAPK inhibition and hyperactivation. By exploring the synergy between established targeted therapy strategies and previously unappreciated pathway activation cancer dependencies, these studies aim to establish a new therapeutic paradigm for cancer treatment. This approach is likely broadly applicable to other key oncogenic signaling pathways and cancer types and addresses one of the fundamental limitations of targeted therapies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $81,580 )
2026	2026	THE BROAD INSTITUTE, INC	415 MAIN ST	CAMBRIDGE	MA	02142	MIDDLESEX	USA	Cancer Research Manpower	000	3	2/12/2026	NON-COMPETING CONTINUATION	$80,224
2026	2026	THE BROAD INSTITUTE, INC	415 MAIN ST	CAMBRIDGE	MA	02142	MIDDLESEX	USA	Cancer Research Manpower	001	3	4/16/2026	NON-COMPETING CONTINUATION	$1,356
														Subtotal = $81,580

Issue Date FY: 2025 ( Subtotal = $78,040 )
2025	2025	THE BROAD INSTITUTE, INC	415 MAIN ST	CAMBRIDGE	MA	02142	MIDDLESEX	USA	Cancer Research Manpower	000	2	3/10/2025	NON-COMPETING CONTINUATION	$76,756
2025	2025	THE BROAD INSTITUTE, INC	415 MAIN ST	CAMBRIDGE	MA	02142	MIDDLESEX	USA	Cancer Research Manpower	001	2	5/22/2025	NON-COMPETING CONTINUATION	$1,284
														Subtotal = $78,040

Issue Date FY: 2024 ( Subtotal = $74,284 )
2024	2024	THE BROAD INSTITUTE, INC	415 MAIN ST	CAMBRIDGE	MA	02142	MIDDLESEX	USA	Cancer Research Manpower	001	1	5/7/2024	NEW	$4,784
2024	2024	BROAD INSTITUTE, INC., THE	415 MAIN ST	CAMBRIDGE	MA	02142	MIDDLESEX	USA	Cancer Research Manpower	000	1	12/26/2023	NEW	$69,500
2024	2024	THE BROAD INSTITUTE, INC	415 MAIN ST	CAMBRIDGE	MA	02142	MIDDLESEX	USA	Cancer Research Manpower	002	1	5/7/2024	NEW	$0
														Subtotal = $74,284

Grand Total All Awards = $233,904

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Directed Clonal Evolution of Drug Resistant BRAF Mutant Melanoma for Cross-Sensitization to MAPK Hyperactivation

Award Number: F32CA271719

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 03/01/2024

PERIOD OF PERFORMANCE END DATE: 02/28/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer